Otakar Semerad1, Tomas Buchler2, Jiri Vejmelka1, Aneta Rozsypalova2, Jitka Tomesova3, Pavel Kohout1. 1. Department of Internal Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 2. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 3. Nutrition Centre, Thomayer Hospital, Prague, Czech Republic.
Abstract
BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04±7.15% to 23.92±7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36±1.75l to 2.77±1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 ± 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.
BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04±7.15% to 23.92±7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36±1.75l to 2.77±1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 ± 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.
Entities:
Keywords:
bioelectrical impedance analysis; body composition; chemotherapy; fat mass; testicular cancer
Authors: Mia Hashibe; Sarah Abdelaziz; Mohammed Al-Temimi; Alison Fraser; Kenneth M Boucher; Ken Smith; Yuan-Chin Amy Lee; Kerry Rowe; Braden Rowley; Micky Daurelle; Avery E Holton; James VanDerslice; Lorenzo Richiardi; Jay Bishoff; Will Lowrance; Antoinette Stroup Journal: J Cancer Surviv Date: 2016-05-11 Impact factor: 4.442
Authors: Haslinda Gould; Sharon L Brennan; Mark A Kotowicz; Geoffrey C Nicholson; Julie A Pasco Journal: Calcif Tissue Int Date: 2014-01-05 Impact factor: 4.333
Authors: H Sagstuen; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; T Wilsgaard; R M Bremnes Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: Denise Halpern-Silveira; Lulie Rosane O Susin; Lúcia R Borges; Silvana I Paiva; Maria Cecília F Assunção; Maria Cristina Gonzalez Journal: Support Care Cancer Date: 2009-07-21 Impact factor: 3.603
Authors: R J Freedman; N Aziz; D Albanes; T Hartman; D Danforth; S Hill; N Sebring; J C Reynolds; J A Yanovski Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958